Navigation Links
ISTO Technologies Awarded Key Patent for NuQu™ Injectable Therapy for Degenerative Disc Disease
Date:2/7/2011

ST. LOUIS, Feb. 7, 2011 /PRNewswire/ -- ISTO Technologies, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted the company a key patent covering the primary technology for ISTO's NuQu™ product.  The new patent, issued on February 1, 2011 as Patent # US-7,879,604, covers the method of cultivating juvenile cartilage cells and injecting those cells into a disc nucleus for the treatment of degenerative disc disease.  

NuQu is an injectable cell-based therapy derived from ISTO's cartilage regeneration platform technology.  It is intended for use as an early intervention treatment for patients suffering from lower back pain.  In preclinical studies, the juvenile chondrocytes used in the NuQu program have shown to be up to 100 times more efficient in producing cartilage matrix than adult cartilage cells.

"The receipt of this patent is an important milestone for the company and is the result of the hard work of many dedicated people over several years.  We believe that our proprietary juvenile chondrocyte-based technology represents a significant potential new treatment option for patients with chronic lower back pain.  Accordingly, an important part of our strategy is to develop a strong intellectual property base to support our product development efforts. We view this recognition by the USPTO of our novel and unique technology as a significant step forward for the NuQu program and for the Company," said Mitchell Seyedin, Ph.D. President & CEO of ISTO.

The company announced the completion of patient enrollment in the Phase I clinical study for NuQu in October 2010.  The study consists of fifteen (15) patients enrolled at two clinical sites. The company anticipates completing data collection of six-month interim results from the trial in early 2011.  All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapies.

In addition to NuQu, the company's other product derived from its cartilage regeneration platform is DeNovo® ET, a scaffold-free engineered cartilage tissue, intended for the repair of damaged articular cartilage in the knee.  DeNovo® ET is developed in partnership with Zimmer, the world's largest provider of reconstructive solutions, and is currently in clinical trials.

In addition to ISTO's cell-based cartilage programs, the company is currently producing and marketing InQu®, a bone graft extender and substitute.  InQu combines integrated hyaluronic acid and a resorbable polymer for better handling and biology. The primary target market for InQu is spinal fusion applications.

About ISTO ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone.  For additional information on ISTO, please visit our website at www.istotech.com. ISTO Technologies, Inc.

Scott Gill

Chief Financial Officer

(314) 995-6049The Ruth Group

Zack Kubow (investors)

(646) 536-7020

zkubow@theruthgroup.comKimberly Muscara (media)

(646) 536-7011

kmuscara@theruthgroup.com
'/>"/>

SOURCE ISTO Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Listing Compliance Plan Accepted by NYSE Amex
2. China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011
3. Long-Term European Data Released for SUPERA® Stent from IDEV Technologies
4. Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase
5. Reportlinker Adds European Markets for Assisted Living Technologies
6. PharmAthene Provides Update on Litigation With SIGA Technologies
7. Advanced Assay Technologies and Development Methods
8. Intrasphere Technologies to Help Develop and Deliver Global Partner Training for the Oracle(R) Argus Safety Suite Through Oracle PartnerNetwork
9. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
10. Nopras Technologies, Inc. Achieves ISO 9001:2008 Certification
11. Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):